Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral danicamtiv improves left atrial contractility in HFrEF

Key clinical point: A novel drug improved myocardial contractility and left atrial volume and function in the setting of heart failure with reduced ejection fraction.

Major finding: The left atrial function index improved by a placebo-corrected 23% in response to danicamtiv.

Study details: This was a phase 2a, randomized, double-blind, 7-day, placebo-controlled clinical trial in 40 patients with heart failure with reduced ejection fraction.

Disclosures: The danicamtiv study was sponsored by MyoKardia. The presenter reported receiving research funding from and serving as a consultant to MyoKardia and numerous other companies.


Voors AA. ESC Heart Failure 2020